

[illegible]

quarter of 2023. The decrease in R&D expenses in the third quarter of 2024 compared to the third quarter of 2023 primarily resulted from the completion of the double-blinded portion of the company's CM-101 Phase 2 PSC trial in the third quarter of 2024.

— General and Administrative (G&A) Expenses: G&A expenses were \$0.9 million for the third quarter of 2024, compared to \$1.0 million for the third quarter of 2023.

— Net Loss: Net loss was \$3.5 million, or a net loss of approximately \$0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to \$4.1 million, or a net loss of approximately \$0.02 per basic and diluted ordinary share for the third quarter of 2023. The weighted average number of ordinary shares outstanding, basic and diluted, was 350,643,531 (equal to approximately 17.5 million ADSs) for the third quarter of 2024.

— Number of issued and outstanding shares: As of September 30, 2024, following completion of its July 2024 financing, the company had 18,856,611 ADSs (representing 377,132,220 ordinary shares) issued and outstanding and 25,469,786 ADSs (representing 509,395,720 ordinary shares) outstanding on a fully diluted basis.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, in particular, the statements regarding our resulting cash runway. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the Company's ability to achieve during the first quarter of 2025 the two milestones mentioned in the press release and ensure its cash runway extends through early 2026; the likelihood that the Company can launch its PSC registrational trial in 2025, and the likelihood that the company can partner with other biopharma companies to accelerate timelines for CM-101 development in PSC and other indications; the risk that the full data set from the CM-101 study or data generated in further clinical trials of CM-101 will not be consistent with the topline results of the CM-101 Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for CM-101 in the U.S., Europe or other territories; failure to successfully commercialize CM-101, if approved by applicable regulatory authorities, in the U.S., Europe or other territories, or to maintain U.S., European or other territory regulatory approval for CM-101 if approved; uncertainties in the degree of market acceptance of CM-101 by physicians, patients, third-party payors and others in the healthcare community; inaccuracies in the Company's estimates of the size of the potential markets for CM-101 or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; development of unexpected safety or efficacy concerns related to CM-101; failure to successfully conduct future clinical trials for CM-101, including due to the Company's potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of CM-101 for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business or agreements with the Company; the strength and enforceability of the Company's intellectual property rights or the rights of third parties; the cost and potential reputational damage resulting from litigation to which the Company may become a party, including product liability claims; changes in laws and regulations applicable to the Company's business and failure to comply with such laws and regulations; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; and inability to repay the Company's existing indebtedness and uncertainties with respect to the Company's need and ability to access future capital; and the intensity and duration of the current war in Israel, and its impact on our operations in Israel. These risks are not exhaustive. You should carefully consider the risks and uncertainties described in the "Risk Factors" sections of our 20-F for the year ended December 31, 2023. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.

About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 activity and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025, including FDA feedback on the design of its planned CM-101 PSC Phase 3 registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com. Contacts: Media & Investors: Chemomab Therapeutics Barbara Lindheim Consulting Vice President Investor & Public Relations, Strategic Communications Phone: +1 917-355-9234 barbara.lindheim@chemomab.com IR@chemomab.com

Condensed Consolidated Balance Sheets (Unaudited)
In USD thousands (except for share amounts) September 30, December 31, 2024 2023

Assets				
Current assets				
Cash and cash equivalents	6,601	9,292		
Short term bank deposits	12,777	10,492		
Restricted cash	75	76		
Other receivables and prepaid expenses	439	1,037		
Total current assets	19,892	20,897		
Non-current assets				
Long term prepaid expenses	428	559		
Property and equipment, net	262	303		
Operating lease right-of-use assets	315	392		
Total non-current assets	1,005	1,254		
Total assets	20,897	22,151		

A A A A A A Current liabilities A A A A A Trade payables A A 386 A A 516 A Accrued expenses A
A 3,124 A A 3,423 A Employee and related expenses A 727 A A 823 A Operating lease liabilities A 112
A A 76 A A A A A A Total current liabilities A 4,349 A A 4,838 A A A A A Non-
current liabilities A A A A A Operating lease liabilities - long term A 230 A A 316 A A A A A
A Total non-current liabilities A 230 A A 316 A A A A A Commitments and contingent
liabilities A A A A A A A A A A A Total liabilities A 4,579 A A 5,154 A A A A A A
A Shareholders' equity (*) A A A A A Ordinary shares no par value - Authorized: 4,650,000,000 shares as of
September 30, 2024, and 650,000,000 shares as of December 31, 2023; Issued and outstanding: 377,132,220 Ordinary
shares as of September 30, 2024, and 284,094,700 as of December 31, 2023; A A - A A - A Additional paid in
capital A 115,978 A A 105,675 A Accumulated deficit A (99,660) A (88,678) A A A A A Total
shareholdersâ€™ equity A 16,318 A A 16,997 A Total liabilities and shareholdersâ€™ equity A 20,897 A A
A 22,151 A (*)A 1 American Depositary Share (ADS) represents 20 Ordinary Shares Interim Condensed Consolidated
Statements of Operations (Unaudited) In USD thousands (except for share and per share amounts) A A Three months
A A Three months A A Nine months A A Nine months A A Ended A A Ended A A Ended A A Ended A A A
September 30, A A September 30, A A September 30, A A September 30, A A A 2024 A A 2023 A A 2024 A A
2023 A Operating expenses A A A A A A A A A A A A A A A A A A Research and
development A 2,836 A A 3,377 A A 8,916 A A 15,284 A A A A A A A A A A A A A
General and administrative A 874 A A 990 A A 2,610 A A 6,327 A A A A A A A A A A A A A
A Total operating expenses A 3,710 A A 4,367 A A 11,526 A A 21,611 A A A A A A A A A A A
A A A A Financing income, net A (227) A (231) A (544) A (807) A A A A A A A A A A A
A A A Loss before taxes A 3,483 A A 4,136 A A 10,982 A A 20,804 A A A A A A A A A A A
A A A Taxes on income A - A A (55) A - A A - A A A A A A A A A A A Net
loss for the period A 3,483 A A 4,081 A A 10,982 A A 20,804 A Basic and diluted loss per Ordinary Share
(*) A 0.010 A A 0.017 A A 0.036 A A 0.092 A Weighted average number of Ordinary Shares outstanding,
basic, and diluted (*) A 350,643,531 A A 236,449,153 A A 306,963,351 A A 226,449,755 A (*)A 1
American Depositary Share (ADS) represents 20 Ordinary Shares GRAPHIC 3 image00001.jpg begin 644
image00001.jpg M_JC_X 02D9)1@ ! 0\$ E@"6 #_VP!# \$! 0\$! 0\$! 0\$! 0\$! 0\$! M 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$!
0\$! 0\$! 0\$! 0\$! 0\$! 0' _MVP!# 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0\$! 0'
P 1" !S 98# 2(A\$! Q\$! \0 M'P 04! 0\$! 0\$ P0%!@<"0H+_0 M1 @\$# P(\$ P4% M! 0 %] 0(#
01!1(A,\$&U\$!)R)Q%##!D:\$((T*QP152? D,V)R@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-
76UJC9VN'BX^3EYN?HZ>KQ(O/T]?;W^/GZ_\0 'P\$ P\$! 0\$! M 0\$! 0 \$" P0%!@<"0H+_0 M1\$ @ \$"! 0#! <%! 0 0)W \$" M
Q\$\$!2\$Q!A)!40=A<1,B,H\$(%*\$1H;'!"2,S4O 58G+1"A8D-.\$E\1<8&1HF M)R@I*C4V-S@Y.D-
\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!
(1 Q\$ /P# ^_BBBB@ H MHMH ***** \._X.3/^"F [5S?MM^+OV4/AW\3/&WPE^#?P?T;P]:W&@^#M
M6OO#DOCOQ)KNE0ZOJ'B'7]2TV:WNM7TZ&&M[#2-/D9;.RD@OI'2XN'CEA^N M/^#6G_@I1^T])8/CA\2/V.?C;\0O\$?
Q;\"6 PKU/XH> M8\9ZKF;4+OPQK%MXCBE^RWEU)'I&HV=NMD%CU*5(VK_P""J' !M!\9S X*9^-
^,MYXQ3?!GXVZ;HJIX:7JIN!:ZK8;/WDL)CM;IIH8HMGKG !*S_@C-^SM P2QTSQGK'@'6O\$ M?
Q+^+WQ&LM/TGQ=_3_%ZVD%Y%X>TV=[VV]+^&=(L\$CL=\$T=M1E>]U"6-7U'6
M9H-. M.YFCTNPCM_V[%(7%)YA/&MY4ZE27LWB:CC*A*BXTZ"P MOPJ4)M:V4\$XNJL.;47^PE%%?(B)]J%%%%%%%%!1110
4444 %%%%!1110 4444 M %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 M4444 %%%!
!1110 4444 %%%%'EGQL^+WA/X# "[QA\5O&LSQZ\X0TN2 F@ M@*"U*
[=EM].TFP60A7O=3OI8+2W!R%:7S7'EQN1 (C^T#_P4L :@^_/B34K MRU\>:\ #KPC),ZZ1X-\#ZA<:/9Z?:+,
[P?:=3M#;ZIJEY;*EQ?7-PJRE,P M6MJC&*OW> X+,6VL\$ L>32:<)&T^V^(GA276UC#'%LT>IP6;R[0?W*ZA+;KE
ML*)W@YW[*_D:K_4'Z\$7A3P3F!/>8^(.9X6ACZ.38/+ \ M/@JEL-
AL3&K1I8W%5<5.K5Q7L_ ;+ #K#TZ,Z<)5O: E7'F<8^CC:678>M5P^' M6'A7J>RG*G*O.I.:M*46I.G",\$E" *Y.3DG:-
OT2_9Z_X*:~M/?_P 2:9<: MGXYU;XD^#\$GB35 !_ C6^GU:&[LFE4W!L=4NFFU+2]0,8(@O(9WC1@//M;F/, M=?UM?
_XV^?V@OASX?^)GPZUBVU31-\$ M=9N "VA/_H1Q:WFL3ZCI&CW5W&\$3;;M_:973X MF>9\,>%^(.<V6I
MXB\$j+P_F<,4YE@JKPM6EC,VH5%[E"#G6Q-&2^U1NIR=-K25-M06DHN+YN;^ MO/XZ?M3_) 9OMM.E^+WC[3?#-
WK"RR:3HRQ76I:YJ,,!'S7-OIG6G-WMK M&Q"-=SI#;&0^4DK2_)70?!CX_P#PA_:#VW'B;X1>-]*8Z;8W"V>II9F:#4 M-
NWC\$76JV:9>B+]921D20M-(;A,M!)[JL1_\$[-TCX,:!(?2[M_P!I M.Q;Q>/[R".=K[QK>76K7>IV,9,4-
Q8:Q)=7[KJ?BA+)&JA>3V\3LR/Ry6=3 M^F/_ OJT7QU)^T-X^US38=3C\!6GPSO].5W ,B:1+K-YK>B3^&+2=3^[EU M-
4@UJYL>#);V@U\$Y1+K\$O\Y<<_1#X-X0\$\S\0,+X@5#;/X4ZM-#>'P
MN8-.OM=/B72+=N2HTX:U:ZG,MUK5M"WVW[/=Z7-= PM:D?QQX?\ "V&XPXD P M^38O&RP-
"=#\$8B4Z2@Z]7V\$(%)4,JGN>TG?F;<9\M.%22A*Q]3Q\FM7)LLJX
MZE_A_K\$X3IP49.2A'VDN7VE1Q3:A';=7E*,>97/[_P!E;JMOJEK]MCPMJGB[MJF3XR>\$OBIIN@7,%EXDM-
\$O&36_#5W=1>=:V^O':=IJ6FM\$;;7HOA)HOP-\4:9\5-2C%XOA M6:_ U+6O#DG@S2;:_ZV\$_B%
[NWU*]T;S4FNK2P@UDPF"*[E[_1YTE)7=KA1117Q9[04444 %%%%!1 M110 4444 %%%%!1110 4444 %%%%!1110
4444 %%%%!1110 4444 %%%% M% !1110 4444 %%%%!1110 4444 %%%%"OAMX?O?%?C_Q3H7@_PYIZ M-
)=ZSX@U*VTRQB"(TA437,B"278C,L,ODF958JAP:%9M&_X*_L<:]K\$&AZ? M)?/'V^[N8[2T-Y<7NGVES<32+%#'%?
WUG;V8,LCDJ;2S1HS\$*&R0!][#E7"/ M%>>X3\$8).&>(,XP.\$39CF&%P[C%3E&MB,+AZM*E*,&IRC.:<8^T
MHZGJ5QF\$H3C3KKX^KT9RUC"K6ITYRN[+E.C;N]-\$]=#Z*() PV) %_P!XJ^ M&OCG3AJ?
A;QAI\$SH^K6P=HIEBG7]W=6=POSVU]93K%=V5S\\%S#%(,[<'^5_MG]H+_@D+^TQ/\\$M\A;HC?&+P3/>2?
V+J.A7&G6OB*&S=F>*+7-#O;JS\FZ
MMXBD<]Q8/<6=S*&DMTA4B!]/ZVK6[M;^V@O;&YM[RSNHDBG;NUFCN+:Y@E4/' M-
!/"SQ312*0R21NR.I!4D'-6*_3?"#Q[X^%,1F\$.&JF!QF5YE4A5S'([H5_MZ^75,71C[.+I+#XC"8O!XR-->QJ5*&
(A&O3C"&)IUO8T'2(K.>\'OSV-/ZV MJD*M)-4L10E&-6.).[@^.;X3@WJE*+Y6VXM)=_F M^+>D?A*? [#6]XAUIJZUBZT^\[47-
K\$Z-)!HFBV4]ZC7%U%O2&[U&6"TMG*R2Q M7.TV]?U0?#CX=^\$?A/X(\-_#SP+I\$&B>%O"Nf6VE:58P*N?
*MXU1KFZE"JUS M?7<@:YO;N3,ESRQ)/:QW'UG\$W'_C']*_B MO)>%J.#PM9T)5J^7/Y-3JX'(MBU&&+SK-
,1BL1B:C5"E*-.6,QF(J*C"?U M? T8UL5*EB.3"Y=DG"&#KXISG%2Y8U<37:j5ZNON4:<81BG=ZJ%. "N_>F[1O M']#OB?\
!?X4?&C2H-\$^WP_+^/-,

#####

M L(T 4+'5K"RU32[RVU#3=2M+>_T^_LYH[FTO;*[B2>UN[6XB9HI]>X@D26& M6-F22-U=6*D&OP^ X+] L ?
#S]L[]A'XI>,IM!T'Z#XU_L[^%-<^*OPQ:Q6T M<6L067AFSDU7Q9X2O+[\$,]QX=U_0;6]:>PFV'""4K6PU'!(KF!9E\)\
^#8O M]JWQ/^T?_P_ \$X\M-&>-]8EUWQ1^S=XXU+X10ZC=327%)X,73[!7O!%O?33, M\LD^F:7J\$VD1.[N38:?
8\C&T<6>X')7K)\1AWYG>\$/^#D7XW? M"7]LK]N_X8_M'_\ ",>- GP4^(?QH^%W[-GPF^'GP]EL?B'\3/GA_XM:]X M(^'?
ANYUVPEU*6X!L=.M(-8NTL(IY;E+B"WDF)/3>*?B]_P=7_!@T23X[M^"/@YX\$^\$OA*X\$ _B/PS\%;0?#RV\8_V
\3V6GVVD^)-OC3_P_ % [!:'B?QMhMCKNE?!+XZ_M_A_ \$71+M2^>16_C=OCAXCT/PWJ+6;@P7:V%OJ&LW^K<)
(D%VMG<)&)\XXIH?!\FOH^,L M9P_PCF^%PN4,Y+C,37RC)\7CWFN'GBL+0E6P5&7U;18.E6H4Z4J;8O%XJ]
MZN(J5*ZA1EAX4Y>U\):>89M@IU<9F6,HTX8O&TL/]5G"E5J1AB:B5:06E"I M*7LW>C1HQ4*<8T^:HJLI1]G
!Y_\\$/^#E?5SKWQ3^ W_!4_P_,;:\%_BO\M*O#GC#7H?&UMH-UX._M_5?!T,M[J'PX|0>!]1E,NC^_KJQ3_(ITV>-
H[.:XL4N.2TW_(?!?!\!/!_2U=:_^*G[W[/GA7]G][E^]>ZM_A[XC]?K MX:L_\$/BJSM[VYABU6#Q#XJOQ<:K=7-
L(#._A[P_]X7M+N*Y@M-(^"P'!)NC:781:-\ M/6'PET'XC7-FBP+?2W/Q(M_TNK>7\$N MPZE)HY*;>=2PPM.
[%=P_OK#^#O#?P]\&^%O_G@1[+P_P""/!^@:3X;
M\Z)IMO':V.EZ/H]E#8V%E:P1*D<<4%O!&@J,D%FRQ),9_B_%DP.1\1Y3P MS@*F.XKP,L6\OS-5L7E&3?4JT)C'@,
(JU/VLL;BH3=/ZU.I#":4:5J5).NO9 M7@*>:8S\$8[+L7F5>-*#;\:"Q.%Y*._+QRKT:>(H?
6:OLYZGX7^(FBZ?)>9W6N1:RQZSINGO(QMX)5FL]*G_M_+>="US2O\$VBZ1XBT*]@U+1==TVRU?2=0M7\$EO>Z=J-
M'=V=U"XX:;>WECDA M^C8.#D5_5_P=A_![PMXS_X)W>/BK?VL4?BSX._&;P?=:!J<<,O)+#QFUQ MX2U?
1I[EH7G.F7"ZG;ZF]M+"K:AI=A.S,(FCD_5+_@CQXOOO\$'_2R_8I_M1^(\VZO+NT_9W"%0ZAJ-
[/+=WEU'HVCK;&ZNB=WFGF:WME,DL2C22,-SL6) M)\B?#Y3FO"V2<6Y=E>%R;&5LRQV1YQ@;=VMU)-%!\S_
0\^'JE^WS_M_,%I/VZ_VV/C-#:^)\3^!'B/6=4)\$Z7J*?;K/2_%'C/Q9XC\&^"-8M%N"\G0H@AM[O4X;RW2*6T@9?
[K:]3_.U_XA[3P?#N0X7!TL]>7X'&_M\0Y]B<^AL;C?K68X6EC89;E[Q5*M2PF\$PV'KT5*I1C[3\$5&IMPE3O/GP>&_U
M@G6S"5JT\ L17H9?@*5:K0H>RPU:5"6)Q*I3A*O6JU:4W&-1\E* &BB^=I?Q
M5>._^"!7_!3][B:+_A<_!. _@H/XZ^)'BOP?:RZA%)\)/%][K/A2[\0PVP-W_M>Z9I;ZAXE\0^_M?O-6\F.TMM(U[1?#T#
[Y4D\0VXFW+^6G_!3_\X+/_!K_M_&J/V2O@;(*B%)0OV:_P!N;X_?"Q?X<^_A[P5J'BOX>0^(M%BV')8P^)
M!%IE_9W&F)=ZQMM[OPU=W5VMM>Q2W=B\VF2V=UN^&+%=8V:_<1Q%/(!0AT=KS3K_MZ[:%[N_1;+
[1]N*!EP'%. "P6,QT*)2KE><4<#A,+C;/4V_M6?U',EAJ%.CCL#B?*M%%UJ+Q%\$^RDJZIRJ)6SRW*,=B,JKUZ-%TU'%8
M.=>M5HN\$ZM-/8;VM24/V7IOE;5.<:4Z7/%TW/E9_XFFN) MYOAGX'EFGN)9)IYI9/#>G)-+*SR2RR,2TDDC,[L2S,6)-?
P4?_WJ]GX-_L_M6?!\Q+_ ,%/VB0CQXEA,\^!/*?M0!R-CZIX@UV[ET*30_"GAZQ+(^H^(/
M\$\$UG+::7):@37)57=2Z[O[T_V?/^2\$?!K_LE_@7_1K3: SW?!\G!&OA!JN; M_@Y5_:#^#WQ\$LH]4^&NB?M#?
%;XG_\$'0YXV>U1>&O=Q;W\OAZ[*L\$6TUG4_MIM/L[M95EANK62:SFADCN6
'PUA@)OCR.:5*]' +O]4,=+&3PRB\3]'&99?. M<,_JG[OVU51]E2<_%A">(_MK#JC&JW&DJCPN+49U" MWO9TV_:34?
>E&+C%IM, 433?^"AO_!PA_P_%)9;[XC?L'_LT>&_V?/V:-22; M_A!O%/CZ#P_:ZKXCL!<2_8M9B\3^,
[^SNM:DU*Q:VE\$GA3PM<^&[:=+A8=:O_M4,4E>0^,?^"M/_!>G_@EYXM.ZG_,%"_P!GG0/B=#K^_M]+N?
\$]GI&C1Z= _M]1FN+(/S)M^)_@2_U33=)UL6SW46G:)XOTS39-3O@FV_6\3/)_<7I&D:5X?T_MK3M#T/3K+2-&TBRMM-
TK2].MHK.PT[3[. %>+TL_.U@5(;>VMX8TBAAB141%"_MJ_!7GOQL^#'_PY_:%^%7CGX,?
%GPSIOBWP!\0O#VH^/'\$6B:I;0W4\$UGJ%N\ 'MVB\$3(XAOK-W6ZL;I_)+:ZBBE0Y7GS,/QED:Q\$')9')JE/#TX8W^UX8
M>Z7M89S+%^WGCE%7=6=-4JDKI4:2:Y>JID^.=+GIY[F,]>UT_\$A@L(MQ7%Q5PC5RG.:^'RF.(Q^4UZ.\$S#+, M4Z;-
P5.KB?9T<5"=;#_MXJDI>['\$86M.A6Y+MODE.FYP3;:C))MM7?!_/\ M4?L3?!'\K?2;6+XBZ3<_MZ=XJTFVFM
^>^'GBL_>\$>EQ2]^+69Y8I;5M-25_M"Z=J4,T,HU,+GRVM[10E_M%5+))O%+W?=VT/*_@W%?AK\O_<G?
#SX6>&K3PUX:TF4Q0EI[W4K156?_M4]7U"8M=:EJ5SL7S[NY=G(58T"1(D:_J57N\NUL+6YOKZX@L['SMYKJ[N[F5
M(+:UM;>-II[BXFD*QPPPQ(DLLC*D:*S,0H)KV/VA/^"V'P"]^^(K_PQ\#_M_(B>+O'M;GQ=K6JS:)X9OS\$SQS/HD-
G;76I7ULLB9@OIOLD%Y"ZS6X:)E_MD;AX.V?*\$KQFSW,O]6KS/BK-I5'CLZS7%XNG&E3JXJ(Q#A4E3A-4ZCC>-
S'+,DP]+ZU6I82BE[.A2A!W<8)>[1HTHN3C!6_MORQY8W2;5U?]R6575D=5='4JRL_RLK##*RG(96!
((((_.#7\X7_!1K_@G!XP_M(>,KS]I/JEW1;XV#7@!\1^*O!WA&.:+7/"FOV\HO)/\$OA.QTY5NYK"YN\$-/_M:::IO-,U'?-
:Q;/3J+/WS]G7_@M5_.OB#XCT_P_*?&[P0/A9+JUV+2T\7:3J_MLNM>%+Y7CBMO[;6[MK74M-@D=R9KZ-
;RUM\$5I+HQ0@RC]O;>X@N[>]"[M]X; MFUN88KBVN;>1)H+BWF19(9X)HRT,/T4>- _M-C'>*LJC./UC#26!\6Q&#KU,/*
<)4ZU"K+%8"I_M4@ZE/V&(J4<1YU:.2\78"5.CB%55*:E3K4KT\3A*UO=GR5(QG#F5TU*+/42=_MG>*E'^9+X+?
(\%K/BSX"T6R)\)?&_X;6GQ"O\1A_9UQXKM+^3PSXFF%BB6S+K_M.F'3[G3+W5?/CE^VW,+.HD^1K/S
[5R/Q]_X*_ _SX:1<_#3X*>!I/AI'X_MF\W29=1V\W>H>)?^'K6UTJJK]BT6>WL+3^QKJZB%Q;R_V9:WVI&*3S-/O[.X1
M09\$ _HD]>_LL?LX_%4EUCX@?!3X<^*=61'C74]3\;X#_M.7D8N1\Q:-OPY_9S^ _PCGFG_AI(_7@N=G=));
[00>>G6E\D8Q&YO?):Z_M#J_.XF#8P.X_%?HDJ&WZ-.\$QJXLPT7>JRXOC/ZW2R^OGG-PG1S)3YU7A@W5J_M8)TH3]^_
%&]&]]FHQ5221Z7J/B'6[A>;3HF,OE64%S?E;J\9YEXA<79_MYQEF^'P&\$Q^>XM8FMA'AR1G5ESU)7;E*4I:.*
[E)NR2C%6C%))(***(^0_M.P*_A4_X.1/A\2OV-O^"A7[*7_!4CX7:3>7.A'4!/VG^)I[!%:V5MX[^&>K
M2ZA%H^M:BD=Q+;I\1_!E_?Z&UT;9UAMM+N(XY!=2VZ-_ =77SM^U7^RW\'/VR_M_@7XY_9Z^_WAB#Q/\^
QWIWV6[A.(M1T?4K9UN=(\1Z#?_>=IFO:%J\$<&H: M7?P,LD%Q"O)1F4_4'\<00X:SW#X_\$T/K>7UJ6(R_-<)9-XG+;?
2EA\92BG*"M@ZFESIFIZ==K'=6MU;O'-&K#%?1%?Y_TO[*?_66_M_P'##?;XL^+?
%W[*(%AKG5/[('B+68KJ)T+1=&UKQSH]]HD5["4OC3X9Z,3K_M_@/QY%8S7VG7'C3P::ZEH,]M%%K.N\$P06.BZ=]B^\$/\
@\$^&GZ,+XQ?L7_M?\$O0_B!9AX-8TKPCXQT.31K._C;#6X/BBWTG6H@%Y=;JPBFC8[#&WWS])C?#
M3,\95EB^#*N'XIR2NW4PM;!8K#+_X6G.THX?,!6]4<3AL324E"HW2Y)>[/] MVZB1\VCQ+A:\$%2SJ%3*
<;!*-6%>E5^KU9[.IA,1",Z56E-IN"4W)6E%W(Y_M']GE9.N\$0]9(((_LK4>1R.+28'IZ'ZU_#MXU_X+8_!%=?"H9G^#O_
3>_M_9\$3?"+PKXLFGTJY^,\5G?ZQ>6>B7!MH;JYN/B+KNG:9V/!-W:I*']R+&)] MU[6+4C3UF?
2+5[QQL78_][OPD^_GP*_8@>#7P?!\VD/&F?#\$XS^<_?A9#X<_M:>*M)U+6M=AU74;QG'FX\0^(:,SXEU""-DMKWQ#?
0VMQK5Q\$U_)6[SM&G_M,[X3QW#F&P]3-L5EU'.*]=4_[&HXVCB\QP]%0'IPO)]2G5XRQTZ4X5/(+^"TITY*
<6X\Y9&24HMJ)9)QD_MKZ233U3.3AB,H9-0C*,HR^LYB[233L\QQ;3L[/5--=TTUHS^&3_@Y_Y2Y?\
M\$QO^OWX7_P#J^M#K]A?^#G;X::_X_P#^"5/Q*U7P]I]YJ<_PZ=_#KQKJEM9_M1^8T'AZS\16UGK>J7_R-
MII5I=F]N7_Y9PQN^"5/Y2_\'\$G@/QSXG_X*O?_M\$W-;\-^"_%OB'1= N?AA-
KFKZ'X;UG5M+T;?;1YVDU34+"RN+2P18(9)F: MZFB"Q(TAP@)K^S3XI?#3P9\9?
AQXW^%Q\$T6U\1>!OB'X9UCPCXJT2]C66VU_M'1=;LY;*]@='#+N\N4O\$Y!,>40Q^_J4%-3
M^K\12Q'LI.\'5A&T;V;4N9::G'0P;QF+XPPLN:G#&O#8>-7E=K5U]5;1Z'K'_!&K_@E;_P_\$K/VT_P#@GA\
/C1X1_9\>+OB/)HE_X_M3^*>JW6MZLF12?#\$PEJ=UHNOS:A_VU[&MFVHRVT>JV,1C02Z;?6=_U\$##/&3^_MHO\Q#[
/!)K_HU/PW_.#G7_\Y85_3:?"_@IW_P;A?'SX@^/(@/\-: M_:N_8!^)/B:ZUZ_TC1=,US7(K+3X[1Q97GBB+0+;4=7^'?
CCP]IL%MI[E]XOE_MT_4/'GB/3-,LXKRXLJJMK73/M2/_@_%_9;_P"";]D?)]H@>)Q\$('TZ/6/AX=
M/_M3_5FW%P^N+J(B%QVF#IGVG^#RM_7U,XR?CG-KC<%
M5R_JBJX&EB:CJ_4=*8^WPU;V,HUZ5;E52+C)SBWR37-&[_6_\!OQ_MP28X!_94_-L2%!UK7@20"3MSJ')!/'0
GH*]T_X*\$^/_/"OPI_X)4_M4?#;_MP-IHT;P=X' 96\=^&?#_E+++NG:+I/A6>TL+9IF>61;>WC2-6D9F(49)-? MSJ]? 'Q_
,%AO^"SG[6OP;^_L]AX^_X_?L6? SQ;%XOT9M/75M!U7QVIB\$<_MUM;6_B&SLKKXC7GB'2)GL'O[O1_ ^'\$T6SO[U[&35-

3M87@_H^X*26%]> \ M!K]LG3=.M+_%;4+G]G?XC6EI9V-I<:CJ>H73^'KF.*"ULK.*:ZO+RYDPL5
MO;0R332L\$BC9V"GX[-:&;8'\BP><\0+~\9#\$X60B<&LRK9E**T53C]6JX MAU*N\$>
(E1A3G5CA:U3V6E*LXR@K^Y@:F%KX?%5L)@'A'+4H4ZTL-#"O%TXT[MJK"GRPK*DI2E&#K4X%/\$GA#5+C]KCQ'?
P.;XHT+5- OY[&7X.?!J M".]AM-5M;2XEM))[:XA2Y2-H7E@FC5R\3A?ZGZGQ*J0J\=<2U*/-(X.5?VV?&.K>"/&&E>\$=5F
M _QBTOQ3J7AC6[#P[J4EQ0/\"MLEAK5W8PZ;+&YBMKB6W^SW,GGQPR20[T0 MM7]P]=?B54IU,UR-
TYPJ*!W#.).XZ?9W%MI\4=M#+<2/=RQ M*D\$;RN1&I.O[+/'@/PG\4?A P**/AMX]T.Q\2^"O'?A;5/"7BSP_J<"7-AK
M&@: ILNF:KIUY!*K1R0W5GIE%+'XVI0 M4U= 5^)*F(JC.S;@ZL(V5[/EES+NE7)Z-)SA M=6ER-O: ^JMN?
CM_P;P_ '+PA\9? \ @E7^SCI7AN^MY=6^#>CZC\O)^FB53>Z M;K7A_ 5;VYC>ZM]QDABU&ROX+NRD=56Y@)DCR
V/V]K^""Q;^RE_P4O\ ^#=_M]I;QI\:/V_!OB3]IS]B7X@WTMOK_@VPL-9\30V^AP2RW.FZ3\0M%T.'4/\$/ MAOQ%X;M9)
[330B7L.G7FFW.FQ2G7C\$[VMO7V1I_>#_L\KH4\$&M?L?_'&'MQRMJ](+[3=^ \$?@B30H]<4&.2VAN+N^@UC[,MT/+
ETQ;O PT0D^49YWP)F> M?9GB[X-A'B')#]#TG3T=E-Q?7-WK E2%,MY-O,1Y<3D?BK_P:/_";7/I!O!WQ M>^)^NJ6]U;;;8?
CS?W/A[[3\$T4=WI_@?P[IOAJZOK+=Q-./JAO;/[0H^:ZLK MJ'N?LF?L&>#-;CUY+O5],U;2M M:%HH(WUK2O\A(;?
3M5^*WCK4M-NKJ'0-0L=+7P7X?C>_2>^~U;I;ZG_ '% ML\? 3X;_ ++WP2^&OP ^\$>BKH/P\^%GA73?"GANQW-
+</:GJM_MEBZ&4X/+;5>.#P5?4\$)5*,L?6Q%>5:K3I5)>QIP49OWX.>N\$E/-)J_N2K^C_@B'X#\
<^/'^"ZO_1/3Q!XA\%^+= "T# M7_B%^T <:'KNL>&]9TS1M9@N/V@_ \$5U;S:7JE[90V-_%<6LL=S;R6L]JSP.L MT1>,
[J_MGKF\3ZE.KQ3STIPJ_ L3AZ/-"2G&(-#T M'4/@_ +KFLZ'X:UO5]*T:)?CK9322ZKJ&G6-S:;%?% CW\$[EW-
"D%NCW\$S)"K M./[7(_N)_N+_ "%1Q;4A/ACPZC&<)2IY'FD:D8R3E3D\ [QIZ)_P \$N?V,-)UK3;_2 M-
5T[X,>' +2 TS5+.YT_4+&Z@C_:.VO+*[CAN;:>)]U*2131)(C AE!IUJDA
MB%^7TU_./M5QOF/;3]A3_@LY^WA^Q\8Y+7PSK?QR\ M0:WIW@K4-0D6SM=6\3^ O%WB;Q?X1T2Q:Y\$?GR>*?!?C?
6M1T]X2T4\^D"WA M>1IXMW]U5?S+_P#!=;_@B9XL_ ;8U;PS^V#^Q_JMOX._;%%MOI4DNG])J3>'(M_BCI_A:
[BU/PU<;;XC@ "2^~/B5X0N8!+X2UMY8;.^VQ:7J=Q8E-/UG2?S>^" M/_!RA^V%^Q3IMA\$?^"HG[/Q-U7QKX1MCH,?
Q&L;]-'@#QCXRGTMCP?;=3TW M7[*Q\%:1+):'M/<>]?"/J/I>M7+S7=E.VUHT0'N9QD]7Q#IX'B/ARKA\9GDL
M!@<#Q#P_+\$4EB,OS&%2A@5B,1B,OS%4YU,+*CB:LL1+#5ZE.,W1Q%&I4J).KRQJP5TU:/ M/_<37\('!WI^U/X,4>+?
V) AS+KGQ7\>I:7\$='O50MY=YJ&F_ :2:%F#P01P&1!YZ&O>? '7_+[5?%_ AMU=R)#;W_-@/\H? "%@K1&Y'ZMXP\5:/I
M6EW<=O-*+U&>)/R)_P""IG_!('XY_LP_LM_! ?X_!RU+QW\?OV[/VDOCEXO MUSXVZIX;/B'QO:>'?#GA%-2M?
#B;.:S0WMU9ZF(7NM2QMK2V9_P"Q=*\$& MCV=C;1^QX=*\?ZL<79-C>+<1A\LQKQ%6GE>3?
6<-6Q]7\$2P];+QF/A1KR67M M#051J]>E"K7K^RA2HU*M)+BXS1YID^H913J8JC[*\$5C/9588>)-J5*!= &'XP?
WXC:KX=U[2/ ^M^_ 6M;:=Z'H4OC\$:<8=.;6+V2..PUG3);R6 MQ:WN-0^PZC%:2VLGSGAS'+JKXXPV:8R&
PF+X4Q>&EBIIR5&I5S/+E2JNG%. M=2-&IRU:L:;< 90J25N6Z]3B)XB*R2IA:+KU:6<4:OLD^5SA#"8OVD%)VC&4
MX7A!R:BZDH1;U\ 28J*>> &U@FN;F6.WMK>*2>XGF=8H8((4,DLTLCD)""& MK/([D*B]68@
FOXQ_AM_P_X*KZ#J7[* _!;'J'E'XL>%=~^(MN?#7CCQZB1ZQXWCTC5+>ZCU M+0G\1:4T?
@3X9.;J5J@AN/%&L^)^H[B2VGNM.LS9WLUI>UPT/'_BJI7BZM' X M?*>;FJ<15,SP\$LCCA5J\9"0Q\$HU:/L_?
@H)U9?"X1G=+6?^\$51BU&I7J8M+_M3+HX7\$+;,'4;25)X:5-3A/F:BW*T\$ _M6/@KPW^S78_P#!?S_@L'_P4(UCX='5 M-1\
(0ZSXV\=:9J^D7- IUM-9Z5XU\)>_].=M0LY(E=-2C2ZNK)'EV:C#;RWU_MLCQ0%HRO![O^"^(?_
2:TS_@EY^SOJMCXROJ]\4 M(&.XTK7_C+XHT>,2:3 MI\$>F6J^'OAQX8O9;>WO;
[P[X4^VZA)/J5XDJZHEKI]G/9:99>GQ M-
XA8VCFKP/#&:8K^PLJPF7Y3E]7FG2^M4LLP=#"2Q2A=.O\$6B^#M2NX25="O%N
M[5;7>,%!J,5@EC*006MIYX^OYK^/0DDDGDDY)/ M?
&OPMM)X;7Q%.EKK_A"ZN9#%:Q^)]\$9[C3H;J559H[74\$>XTV>0#\$27AE8%8 MR#_ \$WX^~^/C?
X7^*=6%^//#.K^&/\$NBW,EMJ&DZM9R6UU"\. BSXMTGP1V_ QJWB?Q+K5S%;V6FZ7:
M2SRGS)4B:XG95\JTLX3(IN;VZ>*TMD^>XFC09K^N#]D_@F? \ ?@5X#T4>._ M
GAGXE_%*JT^";Q7XB\56%OK]A:~.A.B2W.E>='~U!)M/LM,LI MNEPMLUY>F M'[3/<-Y@1?TCZ3_ '@YPSPU@(PV*R;"QC-
X?ZU2J>UQ*Q52OE6)> ITX\M;.%3 MBY49WU5^V3C*%>=>Y9*T\$N9RBW%2_#JW_ (*9?'_JI'4XK32M5U#X2>+!+ M-
MMX0&:YJ=I+>3;@WV[7==MS87^IW/ \$,21VEE;*6"6SR,9J_0#_@CE^UU M\7_"Q'0_ 'XA>)=7;^&QX*O\ Q7X8U'7[Z?
4]6\~W6@WVD65SI\>H7;2W MEQI6I6VK"3R;FXE%I=VB-;A5NY@/K? \ :H_X)% !7XY:K#XK^%]Y9?!'Q/Y;
M1:I9:JH4=QX/UOG,5U)H=M=6 TF_CR5DN-,*P74>T7%HTJ),OM7[\$'_!/?X? M_L:)KVO6NNW7CGXB^)
[*2]1\4WEC'IUMINBI-'=/HVA:>LUT]O;W5W#!R6UHC"*&UBC\Q<>,>OT;W^C_C^%.%&*.4Y[B,'3H9)PQ/(JG]I
MY)G*Q&3S6OQ%*E4HXA4HPG5GCEFE?&9A1E]5Q%M.7M7H_J\DG%-'B*GC,7 MC'7P\9N5?
\$JO:E7H\C7L8X5-%VU64_9QA3DN>M,(R?Z\$5_1%_P]_:-.#7/QS;ZAG:3QIHVF6NM:5XM,VLUW=;5I/BC1[F2!V?1[N
M^NY=/U*PN(KE(KF:VF2:-E*?Q1X>9KP]DW\$%^%QW\$V%CB&6,AA\3 M.'[C\$3PS4O:Q@U*.D*D]J*DDX~LG? \
"+_@V) X*C?M4_ \$[I]?6_P!C/XX_ \$7Q\8?A MUKGPS\0>-/!6K>,[ZZU_Q/X%UWPA=Z)#)96^NW(EO[CP_K>GZIZGX
\%ZA>1. M9([J\\+Z+3=N4'=NSD UW%%-2:V;7HV@*.GZ7IFDP"VTK3K'
M3+88(M)/M+>S@&.F(K:..CM\M7CSP1D'@@@JZ**5P*T%G9VS,]M:6UN[\.T\$ M\$43.,DX9HT4MR2>2>235FBB@"M-
96=PZR3VEM/(F LDT\$4KJ =P"NZ,PP>1@ MC!'Y-6:** (Y8HIXWAGBCFAD4I)%*BR1R*>JNC@JRGN&!!]*XK_A6'PV^W_V
MK_PK[P5_ :8Y^W_ \ "+:)]KSZ^? \ 8?-SWSNSGG.:[FBBF;-J^JFU<"*** M-(8(HX88U"1Q1(L<<:CHJ](@ "JH]!0
/2EDC25&CE1)(W&'210Z,/1E8%6'L0 M13Z*0\$%\$M;VJLEM;P6ZLVYE@BCB5FP!N81JH+8 &2,X '05/110!62SLXI3<
M1VEM'.VXM,D\$22MO^]F14#G= %EN>^:LT44 5IK.SN'66>TMIY\$ "23012.H M'W *[HS* W((P>>M6:** &2(DJ-
*B21NI5XY%#HZG@JRL"K*1P000>]<5) M\,?AO~C5)?_ '@N34ESMOW\+Z(UV,G)(N#9&7)/.=W7GK7<44U)K9M>C:
B@_M@@MHH[>VABMX(EV10P1I%#&Z+%'&%1%HJ@>U2T44@*T=G9PRM-#:6T4SEB
ML< \$22L7.YBTBH'8L>6R3D[G]JS110!6EL]>199[2VFE3 266**210#D]7= M"RX/(P1@U9HHHN!#-
;P7*>7<00SQY#;HDE3(Z';(K#(['13HHHH\$6*&*_ M&->%CB18T4>BH@"C\!4E% !6+JOAKP[KVW^W- T76=F-
GJJZ58ZCLPM:18:H@7.=H6]MYP!GL,"I=%\>~?#0""!6W13N[6N[=NGW %%%%(HHH MH_*Q^(?
P6^\$OQ:MTMOB9\?!WC>*-1'&?\$>A6&HSQQ@Y\$:74T)N4BSSY:S! M,[\$X]47ZQDFG\T>: #WX- "GX36K67PT^'?A#P1
Z>5/(#FA6&FRR1 M9#>5+*QV+K/FK8K&5ZN*Q M-67>I7KSG5F_4FPA"%.*A3A&G!;*(J,5Z1BDE\D?+7[3?
[:]*W[&^D:/K M7[2WQO\ GPEM_\$4TL^AZT4:Q#;:KKLL W3C2=*C\R_O%@3<\J0>2BHXF
MY2M=5^SQ^U%^@S[^UAX(Q%_9U^+/@SXM>\$([MM/O-6\(:O;ZD~U%\$#R:~?JE_MLC"ZTZ\O'F&[AB+;7\LN\$8C_#B?
^#GBS^,\$' !4GQW<_ \$I=6/A.\\">"#\ MIKE+G^QCX^ATYA<0:1P^PO<0^ (7U5]5CM6,\4D]M]N D>(M)A? \&AEE\8&_
M; &^/\^H: FN+\\$X_@;J E^ (TB[AX8D\:/XJT:3X>17&Y=DGB&*S'C"33_);=#I MDFK?;!MGMB?
US%>%N"P_AQ3XT6=2>,> "P^82PLJ=)8*5/\$5Z=%8.%3F]JL5#
MVBCSMRC.O'5'VK^ ^TC\=2XIK5.9Y& \ 'E15211593DZRE3I.K[64;3]JN;>V^T3QVMO]HFC\A^YE#&*WA\QE\V>0(QCA3=
(X5M]JG\KXN\ MPK\A^L[77C)(? GA) @K7+(1Z+9*+769?&/B3S=5MU\$6V&_D\$40DNH
MPLS"/+G;78_M6W>J6.B?V[T32EUS5K?X_?#R2PT=]0324U&<0Z\!;/J4D%
MU'9J5+YSV\R@H%*' =D>@)\3EB,/0I5)OVU*%1R]1A!1=2E[11NIN-ELY2<4 MMW97,/R5."UEN(([FZ\$S6MO) M-
&D]RMN\$, [00LPDF\$ DC,QC5A\$'OOM#+FCJFNZ)H<<[FA5V_Y*J20.2*^3;OQ!X\UO\ :/\ @2GC/X?V_@F*W\+?&A]/

MFM %]IXH M*22U\K/%)':Z5IAL L\;QR*AF\$QD**J%"S. :4TU]5^7[/= MG'X TCXF,VK_ !%
<>]>]J"JZ4TH\SO\,HZWNU)*+?)4 MA32:FF^?V6KCR\VGm-E%MV\SZ\M;VSOK6*^LKNVO+*>/S8;RUGBN+6:+G]Y%
M<0N\,D?!^='*\G@U0TWQ%X?UF6>#1]=T?5I[7_CZATW4[*^EMOFV_OX[6>5 MX?F^7]X%^;CK61IUA#I?
@>*PM]"LO#\$5MX>E0>'M.>&6QT9VL'ET^UEMH;> M"6*VE9T66&")),,UC4-@?FO^SMISZIXO_9EM+3P-:?
#:_P!\$!>,/%]YXW&H M6?VKXNZ%NO\ 1+GPY;VNF1(JVT5_J.G^*M5379A=:??%826D,S37+P+#X.%>
MEBJGM"!8> +I!\R]EB*JNO:~N L5#]TJG+S\]R+83JN\$J4>6 M-_B5O>IQ_ME:7QW]
[EO;E6K/U69E169B%5069F(554#)9B< 9)/ '])&Vnk:@BNK.X@_MN[6=!]QKY\ :C\;R^\$OA1?Z;8?VL^N_\$'5 M-
,^>BQZ!I]YJVNQ_P#"32M!KNIZ7INGQ3WUU<: #X5BUW7%^S0R/&VGJQV\& MN. 9,\0:/9Z9X[^\$.D6?B/3-*^&'B-
9/!ECXLT;6-!UEOAWXNCEUC0"MCKT% MOJ,MCi6L+XD\6UR4>+[/H]O'YF[Y1\$<'6"GBUS>Y4MR\ON^R3A"51SOO[6
MK3A&*B^;]X[KV;3;K)5HTM-8[WUYK.2C:W\D)R;OI]JL^;3ZBO\ Q'X>TN[@ ML-3U[1M.OKK::RO]4L;.[N-
[:,\$BWN)XYIMS_(OEHVYOE&3Q6K+-%!%+//) M'#!#<TKK'%%&I>2661R\$CCC0%G=B%5068@ FO@/XR:#-
XE^/WCC1+?X1 M6?Q7NM5^!&C:~9QZAJ.C:79>'KN[\2:W#!?7-]JFZ[M(GF:.9[G1X+B A6SW M1Q-)Y0KWK6_#NN>\$?
V6/\$?A?Q+K#Z]K_(?^!OB/2=7UHO,[7] 8^";^"XN! M+,QGE!D0JDTI\Z55623\$C-6D\^3C#"M5O?
Q\$J2=/W&XQJQB^=*-1R2BWRM5(MT^:Z<') [3YO>7,E>/V6Y14;O5^[*25O>MH>V:5XD\Z\TR:'K
M^BZR]NJ/<)I6J6.HM DA81M,MG/,8E2 -YJ0RO%*DM[5&HW&E)QLZCM;WERWC*6THQD_ MAM9I;W]?
H: &ZMKEIUM[F"X:UF:WN5AFCE:WN%57:"<1LQAF5'1FBDVN%=6*X M8\$])XX\%0SO:S>+ _"5U%-
]FDMI/\$&DI/'%KL2),^7RF4/N^7;GB MO?@,0WB#JHAE.Y3\>-=4, #N7*>\$/!:.H()&4<,KK_"P((!S7G_B/X4_#2?) MJ7P09_
7A27^T/ACX[UF^:31+%C=ZO%XE\+F+4KC,)KZ+S)?+N9-TR>;)M8 M;N'##4O;5*=2I42AA ;*4(1;;5!5W%J4U:]^5--
VW:\$ZLG"\$HQC[TU%]4FK7 MGR7347?O;3M<^PKB[M;2'[1=7-O;6^Z)//N)HX8=\\B0P)YLC*FZ::2.*)=V M9))\$1
690;?%.O[4P_"!RY51M5?'WP94!>,*/C#X\$ QC QQ].*3]J75]2TO MX4M;V6K7GA^R\2>,_ /@_P 2^(-
/G>TO=\$\)^*O%NE:)XBOK6]C*O82G3;R: MT74\$=&L/M7VM7C,
(=8I89U5AK3L\1B:F'U6D>18=\\VCO*_MW[J5_=25W+1Rj M\OM;QNJ<(ST>KOSZ;:?"M?/R;K'Q3X9U/4+C2=-
\1:%J&JVf [5IECJ^GW> MH6WEG;)]HL[>XDN8?+;Y7R=-IX;!JYJFKZ3H=F^H:UJ>G:/81LJ27VJ7MMI
M]G&SG"*]S=RPPJSGA0S@L>!DUY]X?^"7PE\+3>[OP[V_#.CWWA<2#0]2L- M-AM]2L_/A,-PQU&,"NFNHV;
[6UW/.;IF,D^ ^3YJX;X] #K7/&=Y\.\$6@Z; MX9/77/@#7-7UF?X;^,+IK/0_&=IJ.E?V9,8KGR;RWM==T,2"\T.ZO].OM/CG
MGFAND@%PEU 0IX>I7A15:D*34KSJPA%\T8S<8Z5""*J-1CSSDHTW-N3<8N3;
ME4C!MP3DFO=@VU9M7>L4VXW;LE>22M9NR^A+;ZMKVWAN[.X@N[6YC2:WN;;6 M.>WGAD4-'+#-\$S1RQNI#)
(C,K*05)!HKQWX!ZKX+U/X?I%X&\,7W@C3]'0> M)=%U;P3J*JEWX2\3Z?K-W'XBT)HXKF[M\$@M-4:TT445F4%????
!1110!T_M)?LA?LQ?M:>'.T']I/X& #KXRZ;H5P;K0T\ M;^'K74[O19Y6032:1J@\$.J.;YZ@+
<+97D"3K\LRNO%=5!\ /V=/@5^S)X\$M_A MU^S(\) WP@\$I4>;5ZZD>RIJHZ MJIP55QY'5Y(^T<=^5SMS.-
TG:]O([LHHHKF+"BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH \OL=
TB+XP^(/\$T=F%UR\[' MH]S?>=<\$RZ;9ZQJ-U;6WVMZ=F:XA^S:I8QZBMK=#[/+%YIB\$TH\F;S('W?O(GPN"BNI3G
M[:E+FE=4H).[NDJ5DD]TDM+=M#.RM)65N?:VGQ)_ GKZD_B+0]+O?B-\.=.;?2[OS9T-K#J]JOX?
344\$22K!+]I6RM03/%*T?E PF,LY;R3]I;1 M;.J@\$:T9=5L=8T#5-6DT?5=%U[7/#^HV)U'3&L+X17FA:CIUPT=U:2O!-%+
M))\$R-]S< 045IA9S5?"VE)6IU(K5Z1E*NY17:+SK:+XHO; MJHT[/U5E9]+ +L>K_ X5YOACH*75S?W[2:+%)H[N_6XT?[
MQQ7/VK[1<6]Y8W4]M=VM[]PFGM(YYX99+>"XN4MVB%S/YA=
M:'I<7Q;TCQ+':^7K=UX%UC0KJ]2:X4W.E6VM:7J%M:M:W%NLHM9OLUW-/-;320 M-
<6_VBY2&5(KF=)"BLU*5H+FE98:I%*[LHN523BEVEQ_%?6_\$26H76;KP5I&E3WGG7!FGVVK7MS!;^093;*\$ MGFD?
S\$A69MVUI&4*HZ+QK86FK>#?%NEZA"+BPU+PSKVGWUN7DC\$]G>:5=V]S M"9(GCE02PR.A>-
TD7=E'5@""BHE*7M*+N]J-&SN[JT8VL^ENEMAKX9Z=9?CO M]Y\Q_LS6LFG7VIZ9%JWB6\TW3]!TVTL+#6?%GB?
Q!9V-O;N(88[*VUW5]2AM M?+B18P"1N8U",Q48JU^U1H-
A9:5HOQ#TQ]3T7QMI:3=S:+J%@-0L)+B"*XCMM02ZCMKE/M%JL,Q9R45Z*E+^U;YI7E.\$9.
M[O*,H)2C+NI)M23T:=GHG_8+6]MQKE^TEW?:C>ZEK6M!;_5M6U/4]4N;W4M2U+4+N5Y[J]O[NXN)6(!
MDV(BJNH:'I4WQ5\.>(I;0-K-CX.0:7:WOFW ,5C?:EI<]U!Y"RBV<2RVT#^ M9)"J>7B-U5G#%>?*TO=CJ MM?
=79#LFY:+6*3TW5Y;NM7IYON?\$P7-VG_"Y=:V3:IXOOM!^',A;P9HN MJ>/'&K:5HQ5);2(_8-
3\0W=KJ'V>V8PVG]JQ7WV-\ CU\D@&O9?VF]#L)_ M \BY#J-AXH'WGF^&]>T;6=9T+5-
+JA+/4HH[S1;^PFFM;ZW2..ZLKII[2 M8Q12/ 9(HW4HKTZLY_VCA'S2ORX9?\$]JD4ZBW_Y><[N?^;FES7NSDII?5JBL
MK@_!SPSHOA;X=^';/0[1[:/4;4Z_J,L]Y?:E>ZC
MK>O.=3UC5=1U'4[F\U"^OM0OKB:XN+F[NII&9]H81JB*445Y=:4I5:DI-RDZ 8Dvy2;;;YgJv]6SK@K0@DK)1C9)66R/_9
end